Chih-Jen Yang

Title: Innovations in Lung Cancer Diagnostics by Chih-Jen Yang

Introduction

Chih-Jen Yang is a prominent inventor based in Kaohsiung, Taiwan. He has made significant contributions to the field of lung cancer diagnostics through his innovative research and patented technologies. His work focuses on the development of diagnostic methods that can improve early detection and treatment of non-small cell lung cancers.

Latest Patents

Chih-Jen Yang holds a patent for "Dermcidin-derived peptides for lung cancer diagnostics." This patent outlines methods for diagnosing non-small cell lung cancers by detecting endogenous peptides in exhaled breath condensate (EBC). The patent specifically highlights a dermcidin-derived peptide known as E-R11, which has the sequence ENAGEDPGLAR (SEQ ID NO:2). The levels of the E-R11 peptide in EBC, as measured by mass spectrometry (MS), are shown to be highly diagnostic of non-small cell lung cancers. Additionally, the patent provides a method for inhibiting the growth of lung cancer cells by inhibiting DCD expression through RNA interference.

Career Highlights

Chih-Jen Yang is affiliated with Academia Sinica, where he conducts his research and develops innovative diagnostic methods. His work has garnered attention for its potential impact on lung cancer diagnostics and treatment.

Collaborations

Chih-Jen Yang collaborates with notable colleagues, including Chung-Hsuan Chen and Wei-Chao Chang. Their combined expertise contributes to advancing research in the field of cancer diagnostics.

Conclusion

Chih-Jen Yang's innovative work in lung cancer diagnostics exemplifies the importance of research and development in improving healthcare outcomes. His patented methods and collaborations highlight the potential for significant advancements in cancer detection and treatment.